
Search
Filter Results
Displaying 21–30 of 1125 results
-
- Sep 13, 2025
- 9:00 a.m. - 12:00 p.m. (PDT)
- 2000 Ocean Ave, Santa Monica, CA 90405
The Foundation Fighting Blindness will host the 19th Annual Los Angeles VisionWalk to help light a path in the darkness for the people who are losing, or have already lost, their vision.
-
- Sep 13, 2025
- 9:00 a.m. (CDT)
- 801 W Washington St, Indianapolis, IN 46204
VisionWalk is a community-driven 5K walk that raises funds and awareness to support the Foundation Fighting Blindness in its mission to cure blinding retinal diseases.
-
- Sep 10, 2025
- 6:30 p.m. (EDT)
- 904 Post St, Charlotte, NC 28208
Join us for Vision Connection and a Game.
-
Philadelphia Vision Connection
- Sep 6, 2025
- 2:00 p.m. - 4:00 p.m. (EDT)
- 795 E Lancaster Ave, Villanova, PA 19085
Join the Foundation Fighting Blindness for Vision Connection, an enriching and supportive gathering for the blind and low vision community.
-
From its legendary cowboy culture to world-class art, lush outdoor escapes, and a vibrant food scene, Fort Worth offers something for everyone. Whether you’re exploring the iconic Stockyards, strolling through the Cultural District, or enjoying the city’s lively neighborhoods, you’ll find plenty of ways to make the most of your visit during United in Vision 2026.
-
Postdoctoral Fellowship Award guidelines and application details.
-
Overview and application instructions for the Disease Model Award
-
Aug 25, 2025
Lindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
Aug 22, 2025
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
Aug 20, 2025
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.